Intermittent intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis of two randomized phase III trials (NCT00226408 and ISRCTN75125874) with 980 patients

被引：0
|
作者：
Weichenthal, Michael
Chiarion-Sileni, Vanna
Hauschild, Axel
Del Bianco, Paola
Trefzer, Uwe
Guida, Michele
Enk, Alexander
Romanini, Antonella
Loquai, Carmen
Ridolfi, Ruggero
Schadendorf, Dirk
Mandala, Mario
Koller, Josef
Silvestri, Barbara
Gogas, Helen
Medici, Michele
Dummer, Reinhard
De Salvo, Gian Luca
Mohr, Peter
机构：
[1] Univ Dept Dermatol, Kiel, Germany
[2] Ist Oncol Veneto, Melanoma & Skin Canc Unit, Padua, Italy
[3] Univ Klinikum Schleswig Holstein, Kiel, Germany
[4] Clin Trials & Biostat Unit, Padua, Italy
[5] Charite, Melanoma Ctr, D-13353 Berlin, Germany
[6] Ist Oncol, Bari, Italy
[7] Heidelberg Univ, Hautklin, Heidelberg, Germany
[8] Santa Chiara Univ Hosp Pisa, Pisa, Italy
[9] Johannes Gutenberg Univ Mainz, Univ Med, D-55122 Mainz, Germany
[10] IRST IRCCS, Immunotherapy & Somat Cell Therapy Lab, Meldola, Italy
[11] Univ Klinikum Essen, Essen, Germany
[12] Papa Giovanni XXIII, Div Med Oncol, Unit Clin & Translat Res, Dept Hematol & Oncol, Bergamo, Italy
[13] Landesklin Dermatol, Salzburg, Austria
[14] Gen Hosp, Noale, Italy
[15] Hellen Cooperat Oncol Grp HeCOG, Athens, Greece
[16] Osped Angelo, Mestre Venice, Italy
[17] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[18] Elbeklinikum Buxtehude, Buxtehude, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20028
引用
收藏
页数：1
相关论文
共 33 条
  • [21] A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-α-2b (IFN) in patients (pts) with high risk for melanoma recurrence.
    Kim, K. B.
    Legha, S. S.
    Gonzalez, R.
    Anderson, C.
    Papadopoulos, N. E.
    Eton, O.
    Plager, C.
    Roe, A.
    Liu, P.
    Bedikian, A. Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 453S - 453S
  • [22] United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.
    Tarhini, Ahmad A.
    Lee, Sandra J.
    Hodi, F. Stephen
    Rao, Uma N. M.
    Cohen, Gary Irvin
    Hamid, Omid
    Hutchins, Laura Fulper
    Sosman, Jeffrey Alan
    Kluger, Harriet M.
    Sondak, Vernon K.
    Koon, Henry B.
    Lawrence, Donald P.
    Kendra, Kari Lynn
    Minor, David R.
    Lee, Carrie B.
    Albertini, Mark R.
    Flaherty, Lawrence E.
    Petrella, Teresa M.
    Kirkwood, John M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609
    Laurie E. McLouth
    Yue Zheng
    Stephanie Smith
    F. Stephen Hodi
    Uma N. Rao
    Gary I. Cohen
    Thomas T. Amatruda
    Shaker R. Dakhil
    Brendan D. Curti
    Ibrahim Nakhoul
    Sreenivasa R. Chandana
    Charles L. Bane
    David E. Marinier
    Sandra J. Lee
    Vernon K. Sondak
    John M. Kirkwood
    Ahmad A. Tarhini
    Lynne I. Wagner
    [J]. Quality of Life Research, 2023, 32 : 183 - 196
  • [24] Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609
    McLouth, Laurie E.
    Zheng, Yue
    Smith, Stephanie
    Hodi, F. Stephen
    Rao, Uma N.
    Cohen, Gary, I
    Amatruda, Thomas T.
    Dakhil, Shaker R.
    Curti, Brendan D.
    Nakhoul, Ibrahim
    Chandana, Sreenivasa R.
    Bane, Charles L.
    Marinier, David E.
    Lee, Sandra J.
    Sondak, Vernon K.
    Kirkwood, John M.
    Tarhini, Ahmad A.
    Wagner, Lynne, I
    [J]. QUALITY OF LIFE RESEARCH, 2023, 32 (01) : 183 - 196
  • [25] Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697)
    Agarwala, S. S.
    Lee, S. J.
    Flaherty, L. E.
    Smylie, M.
    Kefford, R. F.
    Carson, W. E.
    Cohen, G.
    Kirkwood, J. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] CNS metastases as a site of progression on SWOG intergroup study S0008: A phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 (BCT) versus high-dose interferon (HDI) in patients with high-risk melanoma
    Samlowski, Wolfram E.
    Moon, James
    Witter, Merle
    Atkins, Michael B.
    Kirkwood, John M.
    Othus, Megan
    Ribas, Antoni
    Sondak, Vernon K.
    Flaherty, Lawrence E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG.
    Flaherty, Lawrence E.
    Moon, James
    Atkins, Michael B.
    Tuthill, Ralph
    Thompson, John A.
    Vetto, John T.
    Haluska, Frank G.
    Pappo, Alberto S.
    Sosman, Jeffrey Alan
    Redman, Bruce G.
    Ribas, Antoni
    Kirkwood, John M.
    Sondak, Vernon K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy
    McMasters, Kelly M.
    Egger, Michael E.
    Edwards, Michael J.
    Ross, Merrick I.
    Reintgen, Douglas S.
    Noyes, R. Dirk
    Martin, Robert C. G., II
    Goydos, James S.
    Beitsch, Peter D.
    Urist, Marshall M.
    Ariyan, Stephan
    Sussman, Jeffrey J.
    Davidson, B. Scott
    Gershenwald, Jeffrey E.
    Hagendoorn, Lee J.
    Stromberg, Arnold J.
    Scoggins, Charles R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) : 1079 - +
  • [29] A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (US Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.
    Tarhini, Ahmad A.
    Lee, Sandra J.
    Hodi, F. Stephen
    Rao, Uma N. M.
    Cohen, Gary I.
    Hamid, Omid
    Hutchins, Laura Fulper
    Sosman, Jeffrey Alan
    Kluger, Harriet M.
    Sondak, Vernon K.
    Koon, Henry B.
    Lawrence, Donald P.
    Kendra, Kari Lynn
    Minor, David R.
    Lee, Carrie B.
    Albertini, Mark R.
    Flaherty, Lawrence E.
    Petrella, Teresa M.
    Kirkwood, John M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Phase ii Study of adjuvant immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose interferon alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: a Single institution, randomized Study
    Mordoh, Jose
    Betina Pampena, Maria
    Aris, Mariana
    Alejandra Blanco, Paula
    Lombardo, Monica
    Maria von Euw, Erika
    Mac Keon, Soledad
    Yepez Crow, Michelle
    Ines Bravo, Alicia
    Manuel O'Connor, Juan
    Gabriela Orlando, Ana
    Ramello, Franco
    Mariel Levy, Estrella
    Marcela Barrio, Maria
    [J]. FRONTIERS IN IMMUNOLOGY, 2017, 8
1234